Prof. Harbeck provides a quick overview of the 5-y data of the monarchE trial- on the role of Adjuvant abemaciclib plus endocrine therapy in HR+, HER2-, high-risk early breast cancer and the Key Opinion Leaders provide a critical assessment of the data and the future of this therapy. They also discuss related presentations and open clinical questions that need to be addressed.
Click on the Chapters icon in the video toolbar to navigate through the sections of the video
Watch Time: 25 min
01.10 - Data critique
06.42 - Survival
08.42 - Biomarkers
14.45 - Other trials
18.38 - Dose reductions, toxicity, and efficacy
21.25 - Expression of receptors in patients, prognostic and predictive markers
23:47 - Summary - Key take home messages